Pharmaceuticals
J INTS BIO, Oral presentation of Preclinical results of its Novel Oral 4th Generation EGFR TKI 'JIN-A02' at the upcoming 2022 World Conference on Lung Cancer in Vienna, Austria
SEOUL, South Korea, June 14, 2022 /PRNewswire/ -- J INTS BIO announced that it
will be presenting the preclinical results of its NSCLC candidate 'JIN-A02' at
the upcoming 2022 IASLC World Conference on Lung Cancer, to be held inVienna,
Austria from 6th to 9th August.
Zhimeng Biopharma will report positive phase 1b trial results on its HBV capsid inhibitor ZM-H1505R in the upcoming International Liver Congress
SHANGHAI, June 14, 2022 /PRNewswire/ -- Shanghai Zhimeng Biopharma announces that it will report the positive results obtained from a phase1b study on its HBV capsid inhibitor ZM-H1505R in the International Liver Congress inJune 22-26, 2022 (the EASL meeting). The recently completed phase 1b stu...
Telix and Invicro Advance AI Partnership
MELBOURNE, Australia and BOSTON, June 14, 2022 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces that it has advanced a partnership with Invicro LLC (Invicro), a global, industry-leading imaging CRO, and part of REALM IDx, Inc., to develop an artificial...
Telix and Invicro Advance AI Partnership
MELBOURNE, Australia and BOSTON, June 14, 2022 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces that it has advanced a partnership with Invicro LLC (Invicro), a global, industry-leading imaging CRO, and part of REALM IDx, Inc., to develop an artificial...
Kintor Pharma and Etana's Collaboration on Pruxelutamide's COVID-19 Project Awarded with Belt and Road Innovation Project and Fund Support from the Science and Technology Department of Jiangsu Province
SUZHOU, China, June 14, 2022 /PRNewswire/ -- Kintor Pharmaceutical Limited ("Kintor Pharma", HKEX: 9939), a clinical-stage biotechnology company developing innovative small molecules and biological therapeutics, today announced that its "clinical trial cooperative research and development and ov...
Alphamab Oncology Announced First Patient Dosed in Phase I Trial of PD-L1/OX40 Bispecific Antibody KN052
SUZHOU, China, June 14, 2022 /PRNewswire/ -- Alphamab Oncology (stock code: 9966.HK) announced that the first patient was dosed in a Phase I clinical study (KN052-CHN-001) of KN052, its proprietary PD-L1/OX40 bispecific antibody, in patients with advanced solid tumors inChina. With the developme...
Innovent and Etana Jointly Announce the Approval of Bevagen® (Bevacizumab Biosimilar) by the Indonesian Food and Drugs Authority (BPOM)
SAN FRANCISCO and SUZHOU, China, June 14, 2022 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for the treatment of oncology, autoimmune, metabolic, ophthalmology and...
Innovent Announces the NMPA Acceptance of the New Drug Application for Tafolecimab Injection (anti-PCSK-9 antibody)
SAN FRANCISCO and SUZHOU, China, June 14, 2022 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of oncology, autoimmune, metabolic, ophthalmology and...
Treadwell Announces Initiation of Patient Dosing in TWT-203, a Phase 1b/2 study of TTK Inhibitor, CFI-402257, in Patients with ER+/Her2- Breast cancer
NEW YORK and HONG KONG, June 14, 2022 /PRNewswire/ -- Treadwell Therapeutics, a clinical-stage biotechnology company developing novel medicines for unmet needs in cancer, today announced the initiation of patient dosing in TWT-203, its Phase1b/2 study to evaluate CFI-402257, an oral, best-in-clas...
Dompé Announces Results of Phase 2 Study Evaluating the Efficacy and Safety of Reparixin in Patients with Severe COVID-19 Pneumonia
* In hospitalized patients with COVID-19 Pneumonia, the rates of clinical events among those treated with Reparixin (n=36) were statistically significantly lower than standard of care (n=19). * The study is the first evaluation of the efficacy and safety of Reparixin an IL-8 inhibitor in pati...
Jubilant Radiopharma Joins Illuccix® Pharmacy Partner Network
MELBOURNE, Australia and INDIANAPOLIS, June 13, 2022 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) is pleased to announce that its prostate cancer imaging agent, Illuccix® (kit for preparation of gallium Ga 68 gozetotide), is now available at selected pharmacies in ...
Novavax COVID-19 Vaccine Nuvaxovid™ Provisionally Registered in Australia as a Booster in Individuals Aged 18 and Over
* In Australia, Nuvaxovid™ is the first protein-based COVID-19 vaccine registered for use as a booster regardless of previous vaccine history GAITHERSBURG, Md., June 13, 2022 /PRNewswire/ -- Novavax, Inc. (NASDAQ: NVAX), a biotechnology company dedicated to developing and commercializing next-...
Curocell announced impressive CR rate in Phase 1 study with anbal-cel, the next generation CD19 CAR-T integrated OVIS™ platform
- 82% ORR (9 of 11 patients) and 82% (9 of 11 patients) CR rate documented after anbal-cel treatment to the patients in relapsed/refractory large B-cell lymphoma - 2 out of 3 patients dosed with 2x105 cells/kg of anbal-cel lasting the complete response for more than 12 months - Well tolerat...
Meness Aptieka earns the Best Place to Work certification in Latvia for 2022
RIGA, Latvia, June 13, 2022 /PRNewswire/ -- Mēness Aptieka, one of the largest pharmacy brands inLatvia, has earned the best place to work certification in Latvia for its first participation. According to the assessment results, 81% of employees said that they are proud to work for the organizati...
Kangpu Announces First Patient Dosed in the US Phase IIa Clinical Trial of NeoMIDES™ Molecular Glue KPG-818 in Systemic Lupus Erythematosus
SHANGHAI, June 12, 2022 /PRNewswire/ -- Kangpu Biopharmaceuticals, a clinical-stage company based inShanghai, China, announced today that the first patient has been dosed in the Company's US Phase IIa clinical trial of KPG-818, an orally bioavailable NeoMIDESTM molecular glue, for the treatment o...
Ascletis Announces Appointment of Mr. John P. Gargiulo, Former North America President and CEO of Daiichi Sankyo, as Chief Business Officer
HANGZHOU, China and SHAOXING, China, June 13, 2022 /PRNewswire/ -- Ascletis Pharma Inc. (HKEX: 1672, "Ascletis"), today announces the expansion of management team with appointment of Mr.John P. Gargiulo, former North America President and CEO of Daiichi Sankyo, as Chief Business Officer. Mr.John ...
Innovent and IASO Bio Present Updated Data of BCMA CAR-T Cell Therapy (Equecabtagene Autoleucel) at EHA 2022
SAN FRANCISCO and SUZHOU, China, June 13, 2022 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of oncology, autoimmune, metabolic, ophthalmology and...
Innovent Releases Results of High-dose Cohorts in Phase 1 Clinical Study of Mazdutide (IBI362) in Chinese Adults with Overweight or Obesity at ENDO 2022
SAN FRANCISCO and SUZHOU, China, June 13, 2022 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of oncology, metabolic, autoimmune, ophthalmology and...
Guojun Lang, CEO of Sanyou: New milestone in the establishment of super-trillion antibody libraries for antibody discovery of challenging targets
SHANGHAI, June 10, 2022 /PRNewswire/ -- Recently, Sanyou Biopharmaceuticals officially launched its independently developed Super-Trillion Antibody Libraries (STAL), and the concomitant innovative antibody drug discovery platform. Established by Sanyou after seven years of continuous innovation a...
Telix and RefleXion Expand Partnership for Prostate Cancer Treatment
MELBOURNE, Australia and INDIANAPOLIS, June 10, 2022 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) and RefleXion Medical, Inc. (Hayward, California, U.S.) (RefleXion) today announced the signing of a co-development and commercialisation agreement, to expand the use ...
Week's Top Stories
Most Reposted
LINKDOOD Breaks Language Barriers, Ushering a New Era for Cross-Border Romance
[Picked up by 326 media titles]
2024-04-29 06:00Multiple achievements made in China-Hungary BRI conference
[Picked up by 314 media titles]
2024-05-03 06:59Dow showcases circular and innovative materials science solutions and industry collaborations at Chinaplas 2024
[Picked up by 293 media titles]
2024-04-30 10:11Xinhua president, Hungarian economy minister vow to bolster media cooperation
[Picked up by 284 media titles]
2024-05-03 06:25TAILG Makes Grand Appearance at 2024 Asiabike Jakarta, Aiming to Set the Benchmark in Indonesia
[Picked up by 259 media titles]
2024-05-02 01:21